2.45Open2.45Pre Close0 Volume2 Open Interest10.00Strike Price0.00Turnover184.01%IV-7.02%PremiumMay 16, 2025Expiry Date2.95Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9138Delta0.0960Gamma2.35Leverage Ratio-0.0197Theta-0.0012Rho-2.15Eff Leverage0.0014Vega
Seres Therapeutics Stock Discussion
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes. 85,742,623. 29,461,090 187,192. 0
Seres Therapeutics Inc - Ser-155 Receives Breakthrough Therapy and Fast Track Designations
Dow Jones· 3 mins ago
Seres' SER-155 Shows Breakthrough Results in Stem Cell Transplant Study, FDA Fast-Track Follows
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
Thursday, 9th January at 7:00 am
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo; data support the broader potential of Seres' live ...
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
No comment yet